-
Stocks to Watch for Wednesday 8/03/2011: Fresh 52 Week Highs and Lows
Wednesday, August 3, 2011 - 1:05am | 5002Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and exit/entry points become more clearly defined. The following stocks hit new 52-week highs in Monday's trading session (listed from highest total volume to...
-
AIDS Healthcare Foundation Hosts Protest & "Die-in" Over Gilead's AIDS Drug Prices
Tuesday, August 2, 2011 - 9:23pm | 101Scores of AIDS advocates are expected to participate in a protest and “die-in” hosted by AIDS Healthcare Foundation tomorrow, Wednesday, August 3rd at 8:00am near the Foster City headquarters of Gilead Sciences (NASDAQ: GILD) to protest the company's pricing of its HIV/AIDS medications. The...
-
NPS Pharmaceuticals Announces New Calcilytics Agreement with GlaxoSmithKline
Tuesday, August 2, 2011 - 4:00pm | 72NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported that it has entered into a new agreement with GlaxoSmithKline (NYSE: GSK), that terminates and replaces a prior collaborative research and license agreement between NPS and GSK from 1993, which focused on the discovery and development of small...
-
NASDAQ's Top Gainers for Monday: PAETEC, Sify Technologies, Dynavax, Limelight Networks
Tuesday, August 2, 2011 - 11:06am | 485POINT ROBERTS - August 2, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Monday, Aug. 01, 2011. PAETEC Holding Corp was the top gainer, climbing 20.60%. PAETEC Holding Corp. (Public, NASDAQ: PAET)...
-
Options Brief: Alkermes
Tuesday, August 2, 2011 - 10:11am | 77Shares of Alkermes (NASDAQ: ALKS) are higher on the session by 3.64%, trading at $17.53. Overall call volume is now running at 7.27x the daily average, with 0% of all calls traded being purchases on the offer. 1,860 contracts have traded on the session so far. Alkermes, Inc. is an integrated...
-
Piper Jaffray Revises EPS Estimates Of Alnylam Pharmaceuticals
Tuesday, August 2, 2011 - 8:10am | 54According to Piper Jaffray, Alnylam Pharmaceuticals (NASDAQ: ALNY), EPS estimates have been revised. Piper Jaffray announced a decrease in FY11 EPS estimates from ($1.31) to ($1.33) and an increase in FY12 EPS estimates from ($1.86) to ($1.82). Rating of neutral and PT of $10 are both reiterated...
-
UPDATE: Piper Jaffray Lowering Price Target On Acorda Therapeutics
Tuesday, August 2, 2011 - 7:31am | 179Piper Jaffray is out with a research report on Acorda Therapeutics (NASDAQ: ACOR) and is lowering its price target to $28 from $30, and it has a Neutral rating on shares. In a note to clients, Piper Jaffray writes, "Acorda reported a 2Q11 GAAP net loss per share of ($0.01), compared to the Street...
-
Oncolytics Biotech Announces Positive Publication of Preclinical Research on Synergistic Combination of Chemotherapy with Oncolytic Virotherapy
Tuesday, August 2, 2011 - 7:27am | 129Oncolytics Biotech Inc. (NASDAQ: ONCY) announced today that an international team of researchers has reported on a study in the online version of Molecular Therapy, a publication of The American Society of Gene and Cell Therapy, investigating the timing of chemotherapy delivery that optimizes the...
-
Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
Tuesday, August 2, 2011 - 7:25am | 194Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the completion of a clinical study that measured lorcaserin concentrations in human cerebrospinal fluid and plasma and related data analyses. The study was conducted to provide additional data that may be informative for...
-
Jefferies Comments on Acquisition at Alkermes
Tuesday, August 2, 2011 - 7:07am | 130Jefferies has published a report on Alkermes (NASDAQ: ALKS) covering a recent acquisition by the biotechnology company. According to Jefferies, "Alkermes posted a strong quarter with impressive top-line growth. With the EDT transaction to close in September, investor focus will be on a successful...
-
Piper Jaffray Lowers PT On Acorda Therapeutics To $28
Tuesday, August 2, 2011 - 6:26am | 27Piper Jaffray has lowered the price target on Acorda Therapeutics (NASDAQ: ACOR) from $30 to $28 and maintains its Neutral rating.
-
Stocks to Watch for Tuesday 8/02/2011: Fresh 52-Week Highs and Lows
Tuesday, August 2, 2011 - 4:20am | 3164Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and exit/entry points become more clearly defined. The following stocks hit new 52-week highs in Monday's trading session (listed from highest total volume to...
-
Insmed Announces Clinical Hold on Arikace Phase 3 Clinical Trials
Monday, August 1, 2011 - 8:33pm | 164Insmed (NASDAQ: INSM) today announced that the U.S. Food and Drug Administration has notified the Company that the agency has placed a clinical hold on Insmed's phase 3 clinical trials for Arikace (liposomal amikacin for inhalation) in Cystic Fibrosis patients with Pseudomonas lung infections and...
-
Rodman & Renshaw Maintains Acorda Therapeutics Market Underperform, $18 PT
Monday, August 1, 2011 - 3:53pm | 116Rodman & Renshaw maintained its Acorda Therapeutics (NASDAQ: ACOR) Market Underperform and $18 price target in a research report published today. In the report, Rodman & Renshaw states, "The company launched a number of initiatives to further increase awareness of walking impairment in MS...
-
Hearing Positive Chatter on Dynavax Tech Due to Upcoming Meeting with Goldman Sachs
Monday, August 1, 2011 - 3:47pm | 146According to a tweet from @markflowchatter, bullish action in Dynavax Tech (NASDAQ: DVAX) may be based on an upcoming meeting the firm has with Goldman Sachs (NYSE: GS) on Tuesday. This article may include mentions of rumors, chatter, or unconfirmed information. Readers should beware that while...